Research Applications
Pigmentation Disorders
Afamelanotide (Melanotan I, Scenesse) is approved for erythropoietic protoporphyria.
Anti-Inflammatory Research
α-MSH and analogs reduce inflammation in models of IBD, arthritis, and neuroinflammation.
Obesity
Setmelanotide (MC4R agonist) is approved for genetic obesity from POMC/LEPR/PCSK1 deficiency.
Sexual Dysfunction
Bremelanotide (PT-141) approved for HSDD.
Mechanism of Action
α-MSH activates melanocortin receptors (MC1R-MC5R), all Gs-coupled GPCRs that increase cAMP. MC1R on melanocytes drives eumelanin synthesis through MITF-mediated tyrosinase expression. MC4R in hypothalamus suppresses appetite through POMC neuron activation. MC1R/MC3R on immune cells suppress NF-κB and reduce pro-inflammatory cytokines. MC4R in PVN stimulates sexual arousal through oxytocin and dopamine pathways.
Biological Pathways
MC1R/cAMP/MITF/tyrosinase for melanogenesis. MC4R/POMC/α-MSH for appetite regulation. MC1R/NF-κB inhibition for anti-inflammation. MC4R/oxytocin/dopamine for sexual function.
Dosage Information
Calculation Results
Syringe Fill Level (100u syringe)
Protocols
No protocols featuring this peptide yet.
Browse All ProtocolsStability & Storage
α-MSH has a short half-life (~minutes) in vivo due to rapid enzymatic degradation. The methionine residue is oxidation-prone. Synthetic analogs with D-amino acid substitutions and cyclization provide enhanced stability for therapeutic use.
Side Effects & Precautions
Nausea, facial flushing, skin darkening (via MC1R), appetite changes. Effects depend on receptor selectivity of the specific analog used.
Research Use Only. This information is for educational and research purposes only. Not intended for medical advice or self-medication.
Regulatory Status
Native α-MSH is an endogenous hormone. Therapeutic analogs are separately regulated: afamelanotide (EMA-approved), setmelanotide (FDA-approved), bremelanotide (FDA-approved).
Research Studies
α-MSH: Anti-Inflammatory and Cytoprotective Actions
Brzoska T, Luger TA, Maaser C, et al.






